Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Neurotrophic effects of potentiating gaba-mediated dendritic inhibition

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Dendritic pathology in aging and depression, and reversal by augmented GABAergic inhibition.


  1. Jacob TC. Neurobiology and therapeutic potential of alpha5-GABA type A receptors. Front Mol Neurosci. 2019;12:179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yao HK, Guet-McCreight A, Mazza F, Moradi Chameh H, Prevot TD, Griffiths JD, et al. Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits. Cell Rep. 2022;38:110232.

    Article  CAS  PubMed  Google Scholar 

  3. Lin CW, Chang LC, Ma T, Oh H, French B, Puralewski R, et al. Older molecular brain age in severe mental illness. Mol Psychiatry. 2021;26:3646–56.

    Article  CAS  PubMed  Google Scholar 

  4. Prevot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26:151–67.

    Article  CAS  PubMed  Google Scholar 

  5. Bernardo A, Lee P, Marcotte M, Mian MY, Rezvanian S, Sharmin D, et al. Symptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress. Neuropsychopharmacology. 2022;47:1608–19.

    Article  CAS  PubMed  Google Scholar 

  6. Prevot TD, Sumitomo A, Tomoda T, Knutson DE, Li G, Mondal P, et al. Reversal of age-related neuronal atrophy by alpha5-GABAA receptor positive allosteric modulation. Cereb Cortex. 2021;31:1395–408.

    Article  PubMed  Google Scholar 

Download references


TP and ES are supported by the Weston Brain Institute, the American Foundation for Suicide Prevention, the Discovery Fund of the Center for Addiction and Mental Health. ES is supported by CIHR. ES and TP are listed inventors on patents covering  the synthesis and use of GABAergic compounds. ES is Founder, acting CEO and CSO of DAMONA Pharmaceuticals, a biopharma dedicated to bringing novel GABAergic compounds to the clinic.

Author information

Authors and Affiliations



TP and ES wrote the manuscript and prepared the figure.

Corresponding authors

Correspondence to Thomas D. Prevot or Etienne Sibille.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Prevot, T.D., Sibille, E. Neurotrophic effects of potentiating gaba-mediated dendritic inhibition. Neuropsychopharmacol. 48, 213–214 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links